NASDAQ$PROK
ProKidney Corp · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Prokidney reported full year 2023 financial results and recent corporate highlights.
ProKidney Corp. reported its full-year 2023 financial results, highlighting positive interim Phase 2 data for rilparencel and key corporate updates, including the appointment of Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer. The company's cash, cash equivalents, and marketable securities totaled $363.0 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2025.
- Dr. Bruce Culleton was appointed as ProKidney CEO in November.
- Nikhil Pereira-Kamath was appointed as Chief Business Officer.
- Positive interim Phase 2 RMCL-002 study data was reported in November, demonstrating the potential of rilparencel to preserve kidney function.
- Manufacturing has been temporarily paused while ProKidney amends the PROACT 1 protocol.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2023
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro